BAKER BROS. ADVISORS LP - 24 Jun 2026 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: KYMR
Reported as of: 24 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Jun 2026, 17:10:52 UTC
Prior SEC filing: 18 Jun 2026
Next SEC filing: 29 Jun 2026
Source filing: View source filing
Reporting owner signature: By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing

Key filing fact

BAKER BROS. ADVISORS LP filed Form 4 for Kymera Therapeutics, Inc. (KYMR) on 25 Jun 2026.

Key facts

This page summarizes BAKER BROS. ADVISORS LP's Form 4 filing for Kymera Therapeutics, Inc. (KYMR).
2 reported transactions and 12 derivative rows are listed below.
Accepted by SEC: 25 Jun 2026, 17:10.

Change

Previous filing in this sequence was filed on 18 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (6)

CIK 0001263508 Primary reporting owner

BAKER BROS. ADVISORS LP

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Signature date: 25 Jun 2026

CIK 0001551139

667, L.P.

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Signature date: 25 Jun 2026

CIK 0001580575

Baker Bros. Advisors (GP) LLC

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Signature date: 25 Jun 2026

CIK 0001363364

Baker Brothers Life Sciences LP

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP to Baker Brothers Life Sciences, L.P., /s/ Name: Scott L. Lessing, Title: President
Signature date: 25 Jun 2026

CIK 0001087940

BAKER FELIX

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: /s/ Julian C. Baker
Signature date: 25 Jun 2026

CIK 0001087939

BAKER JULIAN

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: /s/ Felix J. Baker
Signature date: 25 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KYMR transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +6,068
Change %
Price: $0.000000^*
Shares after: 6,068
Date: 24 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 6,068
Exercise price: $99.87
Footnotes: F1, F2, F3, F4, F5, F6

KYMR transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +6,068
Change %
Price: $0.000000^*
Shares after: 6,068
Date: 24 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 6,068
Exercise price: $99.87
Footnotes: F1, F2, F3, F4, F5, F6

KYMR transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +6,068
Change %
Price: $0.000000^*
Shares after: 6,068
Date: 24 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 6,068
Exercise price: $99.87
Footnotes: F1, F2, F3, F4, F5, F6

KYMR transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +6,068
Change %
Price: $0.000000^*
Shares after: 6,068
Date: 24 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 6,068
Exercise price: $99.87
Footnotes: F1, F2, F3, F4, F5, F6

KYMR transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +6,068
Change %
Price: $0.000000^*
Shares after: 6,068
Date: 24 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 6,068
Exercise price: $99.87
Footnotes: F1, F2, F3, F4, F5, F6

KYMR transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +6,068
Change %
Price: $0.000000^*
Shares after: 6,068
Date: 24 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 6,068
Exercise price: $99.87
Footnotes: F1, F2, F3, F4, F5, F6

KYMR transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +6,068
Change %
Price: $0.000000^*
Shares after: 6,068
Date: 24 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 6,068
Exercise price: $99.87
Footnotes: F1, F2, F3, F4, F6, F7

KYMR transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +6,068
Change %
Price: $0.000000^*
Shares after: 6,068
Date: 24 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 6,068
Exercise price: $99.87
Footnotes: F1, F2, F3, F4, F6, F7

KYMR transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +6,068
Change %
Price: $0.000000^*
Shares after: 6,068
Date: 24 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 6,068
Exercise price: $99.87
Footnotes: F1, F2, F3, F4, F6, F7

KYMR transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +6,068
Change %
Price: $0.000000^*
Shares after: 6,068
Date: 24 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 6,068
Exercise price: $99.87
Footnotes: F1, F2, F3, F4, F6, F7

KYMR transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +6,068
Change %
Price: $0.000000^*
Shares after: 6,068
Date: 24 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 6,068
Exercise price: $99.87
Footnotes: F1, F2, F3, F4, F6, F7

KYMR transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +6,068
Change %
Price: $0.000000^*
Shares after: 6,068
Date: 24 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 6,068
Exercise price: $99.87
Footnotes: F1, F2, F3, F4, F6, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

6,068 non-qualified stock options ("Stock Options") exercisable solely into common stock ("Common Stock") of Kymera Therapeutics, Inc. (the "Issuer") were granted under the Issuer's 2020 Stock Option and Incentive Plan to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") in his capacity as a director of the Issuer. The Stock Options have a strike price of $99.87 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Felix J. Baker's continued service on the board of directors of the Issuer (the "Board") through such vesting date and expire on June 23, 2036. Felix J. Baker serves on the Board as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds").

Footnote F2

Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Felix J. Baker does not have any right to any of the Issuer's securities issued as part of his service on the Board and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the Stock Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interests in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options and any Common Stock acquired upon the exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service. Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock acquired as a result of the exercise of the Stock Options.

Footnote F3

The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds.

Footnote F4

Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

Footnote F5

After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

Footnote F6

The acquisition of Stock Options reported on this form represents a single grant to Felix J. Baker of 6,068 Stock Options on Table II. This grant of 6,068 Stock Options to Felix J. Baker is reported for each of the Funds as each has an indirect pecuniary interest in such securities.

Footnote F7

After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC remarks

Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC is a director of Kymera Therapeutics, Inc. (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons other than Felix J. Baker are deemed directors by deputization of the Issuer.